Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BDTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Black Diamond Therapeutics Inc

BDTX
Current price
3.04 USD +0.09 USD (+3.05%)
Last closed 2.95 USD
ISIN US09203E1055
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 155 803 520 USD
Yield for 12 month -48.91 %
1Y
3Y
5Y
10Y
15Y
BDTX
21.11.2021 - 28.11.2021

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: One Main Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.67 USD

P/E Ratio

45.67

Dividend Yield

Financials BDTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

+70 000 000 USD

Last Quarter

Current Year

Last Year

-437 000 USD

Current Quarter

+70 000 000 USD

Last Quarter

EBITDA -716 000 USD
Operating Margin TTM 77.90 %
Price to Earnings 45.67
Return On Assets TTM -0.42 %
PEG Ratio
Return On Equity TTM 4.14 %
Wall Street Target Price 10.67 USD
Revenue TTM 70 000 000 USD
Book Value 2.50 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM 70 000 000 USD
Earnings per share 0.060 USD
Diluted Eps TTM 0.060 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin 7.27 %

Stock Valuation BDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 45.67
Forward PE
Enterprise Value Revenue 0.28
Price Sales TTM 2.23
Enterprise Value EBITDA -1.92
Price Book MRQ 1.06

Technical Indicators BDTX

For 52 Weeks

1.20 USD 6.75 USD
50 Day MA 2.19 USD
Shares Short Prior Month 6 835 909
200 Day MA 2.39 USD
Short Ratio 5.20
Shares Short 5 805 076
Short Percent 17.27 %